Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q4 2025 vs. Q3 2025
How the institutions holding Gain Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 38 | 1 | 48 | +11 |
| Shares | 4.34M | 4.44K | 8.06M | +3.72M (+85.8%) |
| Value | $7.70M | $7.86K | $25.9M | +$18.2M (+237.1%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (21)
Institutions that held Gain Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Potomac Capital Management, Inc. | 1,010,000 | $3.25M | 2.72% |
| Cresset Asset Management, LLC | 160,000 | $515.2K | 0.00% |
| LPL Financial LLC | 106,550 | $343.1K | 0.00% |
| Colony Group, LLC | 77,855 | $250.7K | 0.00% |
| Simplex Trading, LLC | 47,946 | $154.4K | 0.00% |
| Omers Administration Corp | 37,300 | $120.1K | 0.00% |
| Goldman Sachs Group Inc | 32,494 | $104.6K | 0.00% |
| Point72 Asset Management, L.P. | 32,480 | $104.6K | 0.00% |
| Lighthouse Investment Partners, LLC | 23,040 | $74.2K | 0.00% |
| Gsa Capital Partners LLP | 20,472 | $66.0K | 0.01% |
| Oliver Luxxe Assets LLC | 20,250 | $65.2K | 0.01% |
| Apollon Wealth Management, LLC | 19,825 | $63.8K | 0.00% |
| Wealthspire Advisors, LLC | 16,900 | $54.4K | 0.00% |
| Engineers Gate Manager LP | 14,617 | $47.1K | 0.00% |
| Millennium Management LLC | 14,002 | $45.1K | 0.00% |
| Commonwealth Equity Services, LLC | 12,685 | $40.9K | 0.00% |
| Sprott Inc. | 12,000 | $38.6K | 0.00% |
| BNP Paribas Arbitrage, SA | 2,381 | $7.67K | 0.00% |
| FNY Investment Advisers, LLC | 2,000 | $6.00K | 0.00% |
| State of Wyoming | 1,438 | $4.63K | 0.00% |
| Larson Financial Group LLC | 10 | $32 | 0.00% |
Sold out (10)
Institutions that held Gain Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Citadel Advisors LLC | 373,558 | $661.2K |
| Virtu Financial LLC | 54,008 | $96.0K |
| XTX Topco Ltd | 54,202 | $95.9K |
| Kovitz Investment Group Partners, LLC | 47,578 | $84.2K |
| Squarepoint Ops LLC | 38,537 | $68.2K |
| Two Sigma Securities, LLC | 27,323 | $48.4K |
| JPMorgan Chase & Co | 26,280 | $46.5K |
| HighTower Advisors, LLC | 11,574 | $20.5K |
| Armis Advisers, LLC | 10,750 | $19.8K |
| SRS Capital Advisors, Inc. | 3,250 | $5.75K |
Not filed for Q4 2025 yet (1)
Institutions that held Gain Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Creekmur Asset Management LLC | 4,440 | $7.86K |